For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Research and development | 12,034 | 12,340 | 12,042 | 67,197* |
| General and administrative | 7,337 | 7,195 | 7,223 | 9,540* |
| Total operating expenses | 19,371 | 19,535 | 19,265 | 76,737 |
| Loss from operations | -19,371 | -19,535 | -19,265 | -76,737* |
| Other income, net | 1,791 | 1,892 | 2,100 | 2,168* |
| Net loss | -17,580 | -17,643 | -17,165 | -74,569* |
| Unrealized gain on marketable securities | 84 | -19 | -15 | -515* |
| Total comprehensive loss | -17,496 | -17,662 | -17,180 | -75,084 |
| Basic EPS | -0.65 | -0.65 | -0.08 | -1.762 |
| Diluted EPS | -0.65 | -0.65 | -0.08 | -1.762 |
| Basic Average Shares | 26,963,107 | 26,949,752 | 215,410,253 | 42,618,810 |
| Diluted Average Shares | 26,963,107 | 26,949,752 | 215,410,253 | 42,618,810 |
RAPT Therapeutics, Inc. (RAPT)
RAPT Therapeutics, Inc. (RAPT)